Glycan-based Biological Degraders Targeting the Cytokine Immune Axis
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Targeted degradation of extracellular proteins via lysosomal pathways offers a promising therapeutic strategy by enabling irreversible target removal and potentially reducing systemic effects of antigen accumulation. In this study, we present a modular platform for the design and evaluation of Biological Degraders (BioDegs) that leverage receptor-mediated uptake through triantennary N-acetylgalactosamine (TGN) induced activation of the asialoglycoprotein receptor (ASGPR). Using interleukin-6 (IL-6) and its soluble receptor (sIL-6R) as therapeutically relevant model antigens, we systematically compared a range of BioDeg formats, including full-length antibodies (siltuximab, tocilizumab), a VHH against IL-6, and an IL-6 binding decoy-receptor design, with respect to binding affinity, thermal stability, cellular uptake, lysosomal trafficking, and degradation efficiency in HepG2 cells. Our results demonstrate that both scaffold architecture and receptor engagement critically influence degradation outcomes. This work provides a comparative framework for BioDeg design and highlights key parameters for developing lysosome-targeting degraders for extracellular proteins.
